ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

ClinicalTrials.gov ID: NCT05966493

Public ClinicalTrials.gov record NCT05966493. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)

Study identification

NCT ID
NCT05966493
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Glaukos Corporation
Industry
Enrollment
84 participants

Conditions and interventions

Interventions

  • Vehicle Drug
  • lufepirsen high dose Drug
  • lufepirsen low dose Drug

Drug

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 16, 2023
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025
Last update posted
Jul 23, 2025

2023 – 2025

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Glaukos Investigative Site Dothan Alabama 36301 Recruiting
Glaukos Investigative Site Petaluma California 94954 Recruiting
Glaukos Investigative Site Torrance California 90505 Recruiting
Glaukos Investigative Site Colorado Springs Colorado 80924 Recruiting
Glaukos Investigative Site Grand Junction Colorado 81501 Recruiting
Glaukos Investigative Site Bradenton Florida 34209 Recruiting
Glaukos Investigative Site Fort Myers Florida 33907 Recruiting
Glaukos Investigative Site South Miami Florida 33143 Recruiting
Glaukos Investigative Site Atlanta Georgia 30339 Recruiting
Glaukos Investigative Site Carmel Indiana 46032 Recruiting
Glaukos Investigative Site Fraser Michigan 48026 Recruiting
Glaukos Investigative Site Kansas City Missouri 64133 Recruiting
Glaukos Investigative Site Kansas City Missouri 64154 Recruiting
Glaukos Investigative Site Palisades Park New Jersey 07650 Recruiting
Glaukos Investigative Site Shelby North Carolina 28150 Recruiting
Glaukos Investigative Site Bala-Cynwyd Pennsylvania 19004 Recruiting
Glaukos Investigative Site Nashville Tennessee 37215 Recruiting
Glaukos Investigative Site Houston Texas 77025 Recruiting
Glaukos Investigative Site San Antonio Texas 78209 Recruiting
Glaukos Investigative Site Madison Wisconsin 53705 Recruiting
Glaukos Investigative Site Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05966493, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05966493 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →